Haraoui B - Search Results

1

Differentiating the efficacy of the tumor necrosis factor inhibitors.

Haraoui B. Haraoui B. Semin Arthritis Rheum. 2005 Apr;34(5 Suppl1):7-11. doi: 10.1016/j.semarthrit.2005.01.003. Semin Arthritis Rheum. 2005. PMID: 15852248 Review.

2

Safety and efficacy of long-term intraarticular steroid injections in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled trial.

Raynauld JP, Buckland-Wright C, Ward R, Choquette D, Haraoui B, Martel-Pelletier J, Uthman I, Khy V, Tremblay JL, Bertrand C, Pelletier JP. Raynauld JP, et al. Among authors: haraoui b. Arthritis Rheum. 2003 Feb;48(2):370-7. doi: 10.1002/art.10777. Arthritis Rheum. 2003. PMID: 12571845 Clinical Trial.

3

Quantitative magnetic resonance imaging evaluation of knee osteoarthritis progression over two years and correlation with clinical symptoms and radiologic changes.

Raynauld JP, Martel-Pelletier J, Berthiaume MJ, Labonté F, Beaudoin G, de Guise JA, Bloch DA, Choquette D, Haraoui B, Altman RD, Hochberg MC, Meyer JM, Cline GA, Pelletier JP. Raynauld JP, et al. Among authors: haraoui b. Arthritis Rheum. 2004 Feb;50(2):476-87. doi: 10.1002/art.20000. Arthritis Rheum. 2004. PMID: 14872490

4

Is there a rationale for switching from one anti-tumor necrosis factor agent to another?

Haraoui B. Haraoui B. J Rheumatol. 2004 Jun;31(6):1021-2. J Rheumatol. 2004. PMID: 15170907 Review. No abstract available.

5

Adalimumab therapy in rheumatoid arthritis.

Keystone E, Haraoui B. Keystone E, et al. Among authors: haraoui b. Rheum Dis Clin North Am. 2004 May;30(2):349-64, vii. doi: 10.1016/j.rdc.2004.02.004. Rheum Dis Clin North Am. 2004. PMID: 15172045 Review.

6

Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept.

Haraoui B, Keystone EC, Thorne JC, Pope JE, Chen I, Asare CG, Leff JA. Haraoui B, et al. J Rheumatol. 2004 Dec;31(12):2356-9. J Rheumatol. 2004. PMID: 15570634 Clinical Trial.

7

The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis.

Haraoui B. Haraoui B. J Rheumatol Suppl. 2005 Jan;72:46-7. J Rheumatol Suppl. 2005. PMID: 15660467 Review.

8

Differentiating the efficacy of tumor necrosis factor inhibitors.

Haraoui B. Haraoui B. J Rheumatol Suppl. 2005 Mar;74:3-7. J Rheumatol Suppl. 2005. PMID: 15742457 Review.

9

Musculoskeletal manifestations and autoimmune diseases related to new biologic agents.

Haraoui B, Keystone E. Haraoui B, et al. Curr Opin Rheumatol. 2006 Jan;18(1):96-100. doi: 10.1097/01.bor.0000198007.73320.6e. Curr Opin Rheumatol. 2006. PMID: 16344625 Review.

10

Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.

Haraoui B, Cameron L, Ouellet M, White B. Haraoui B, et al. J Rheumatol. 2006 Jan;33(1):31-6. J Rheumatol. 2006. PMID: 16395747

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results